Tango Therapeutics announced plans for a pivotal Phase III study of vopimetostat (TNG‑462), a next‑generation PRMT5 inhibitor designed to exploit MTA cooperativity in MTAP‑deleted tumors, based on promising Phase I/II data in pancreatic ductal adenocarcinoma. The company concurrently raised $225 million to fund late‑stage development and expansion of clinical cohorts. Early clinical results showed objective responses and progression‑free survival improvements versus historical chemotherapy benchmarks in a hard‑to‑treat PDAC population. Tango positioned the Phase III as a biomarker‑driven, indication‑specific program and signaled intentions to engage regulators on trial design and endpoints.